Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT07283575

Using ctDNA Methylation to Monitor Metastatic Colorectal Cancer Treatment (PROMET)

Sponsor: Fudan University

View on ClinicalTrials.gov

Summary

Multi-center observational clinical study to evaluate the application value of ctDNA methylation monitoring in efficacy assessment and relapse prediction in patients diagnosed with recurrence or metastatic colorectal cancer receiving radiotherapy plus SOC with or without PD-1.

Official title: ctDNA Methylation for Efficacy Assessment and Prognostic Prediction in Advanced Colorectal Cancer Treated With Radiotherapy Combined With or Without PD-1 Inhibitor: A Prospective Cohort Study (PROMET)

Key Details

Gender

All

Age Range

18 Years - 75 Years

Study Type

OBSERVATIONAL

Enrollment

497

Start Date

2025-10-10

Completion Date

2030-10-10

Last Updated

2025-12-16

Healthy Volunteers

No

Interventions

DIAGNOSTIC_TEST

Plasma ctDNA methylation profiling

Plasma ctDNA methylation profiling was performed using an optimized single-tube multiplex mqMSP assay

Locations (1)

Fudan University Shanghai Cancer Center

Shanghai, China